- Patients must have histologically or cytologically confirmed intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, or gallbladder cancer.
- Patients must have documented metastatic or locally advanced unresectable disease on CT or MR imaging.
- Patient must not have a current diagnosis of ampullary cancer.
- Patients must not have received prior systemic therapy for the current metastatic or locally advanced biliary cancer.
- Patient must not have received adjuvant therapy within 6 months prior to registration.
- Patients must have a Zubrod Performance Status of 0 or 1.
Please contact Legacy Oncology Research for additional study inclusion/exclusion information.